Discovery of ligands for directed-differentiation of stem cells

干细胞定向分化配体的发现

基本信息

  • 批准号:
    8240375
  • 负责人:
  • 金额:
    $ 19.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-12-15 至 2013-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In addition to discovering soluble small molecule for hESC/iPSC maintenance and directed differentiation, combinatorial chemistry can also serve as an excellent tool for the identification of extracellular matrix (ECM) mimics that can further facilitate the maintenance or specific- differentiation of hESC/iPSCs. The one-bead-one-compound (OBOC) combinatorial chemistry invented by Dr. Lam is particularly suited for the discovery of ECM mimics or other functional ligands against unique cell surface receptors of stem cells. We have recently developed a one- bead-two-compound (OB2C) library method by incorporating a known cell adhesion peptide (e.g. an integrin binding ligand) on the outer layer of every bead of the OBOC library. As a result, every bound cell will be exposed to the library compound displayed on the surface of each bead. We have generated genetically-labeled Olig2-GFP knock-in hESC/iPSC reporter lines that can be conveniently used as readouts in the proposed combinatorial library screening for directed-differentiation toward various lineages. Specific aims of this proposal are: 1. To design and synthesize several OBOC and OB2C combinatorial libraries for the discovery of cell surface acting molecules that can induce directed-differentiation of hESCs or iPSCs. 2. To use live Olig2-GFP knock-in reporter hESC/iPSC lines in conjunction with immunocytochemical methods to screen various OB2C libraries (from aim 1) for directed-differentiation into oligodendroglial progenitor cells. 3. To fully characterize effects of the ligands and molecules identified in aim 2 on hESC/iPSC growth and differentiation using a range of biological and biochemical approaches. To optimize and use these ligands in a novel chemically-defined self- assemble PVA-based hydrogel as artificial ECM to support stem cell growth and directed- differentiation into oligodendroglial progenitor cells [OPCs]. Impact The proposed research will enable us to discover synthetic molecules that bind to unique receptors on the surface of hESC/iPSCs. Some of these molecules may support the growth of hESC/iPSCs while maintaining its "stem-ness". Others may induce specific cell signaling and oligodendrocyte differentiation. Our long term goal is to direct-differentiate oligodendrocyte precursor cells further for the treatment of neurological diseases. PUBLIC HEALTH RELEVANCE: In addition to discovering soluble small molecule for hESC/iPSC maintenance and directed differentiation, combinatorial chemistry can also serve as an excellent tool for the identification of extracellular matrix (ECM) mimics that can further facilitate the maintenance or specific- differentiation of hESC/iPSCs. The one-bead-one-compound (OBOC) and one-bead-two- compound (OB2C) combinatorial chemistry invented by Dr. Lam is particularly suited for the discovery of ECM mimics or other functional ligands against unique cell surface receptors of stem cells. Genetically-labeled Olig2-GFP knock-in hESC/iPSC reporter lines will be used as readouts in the proposed combinatorial library screening for directed-differentiation into oligodendroglial progenitor cells.
描述(由申请人提供):除了发现用于HESC/IPSC维护和定向分化的可溶性小分子外,组合化学还可以作为鉴定细胞外基质(ECM)模拟物的绝佳工具,可以进一步促进HESC/IPSC的维持或特定差异。 LAM博士发明的单珠一个组合(OBOC)组合化学特别适合发现ECM模拟物或其他功能性配体针对干细胞的独特细胞表面受体。我们最近通过在OBOC库的每个珠子的外层上掺入已知的细胞粘附肽(例如整联蛋白结合配体),开发了一种单珠 - 两种化合物(OB2C)库方法。结果,每个绑定的单元将暴露于每个珠子表面上显示的库化合物。我们已经生成了遗传标记的Olig2-GFP敲入HESC/IPSC报告基因线,可以方便地用作建议的组合库筛选中的读数,以定向划分各种谱系。该提案的具体目的是:1。设计和合成几个OBOC和OB2C组合库,以发现可以诱导hESCS或IPSC的指示分化的细胞表面作用分子。 2。将活的Olig2-GFP敲入报告基因hESC/IPSC系列与免疫细胞化学方法结合使用,以筛选各种OB2C文库(来自AIM 1),将定位分化为寡头祖细胞。 3。用一系列生物学和生化方法完全表征AIM 2中鉴定的配体和分子对HESC/IPSC生长和分化的影响。为了在一种新型的化学定义的基于PVA的水凝胶作为人工ECM中优化和使用这些配体,以支持干细胞的生长并将其定向 - 分化为寡胶质祖细胞[OPC]。影响拟议的研究将使我们能够发现与HESC/IPSC表面上独特受体结合的合成分子。这些分子中的一些可以支持hESC/IPSC的生长,同时保持其“干性”。其他可能诱导特定的细胞信号传导和少突胶质细胞分化。 我们的长期目标是将少突胶质细胞前体细胞进一步指导以治疗神经系统疾病。 公共卫生相关性:除了发现用于hESC/IPSC维护和定向分化的可溶性小分子外,组合化学还可以作为鉴定细胞外基质(ECM)模拟的绝佳工具,可以进一步促进HESC/IPSC的特定差异。 Lam博士发明的单珠单螺旋(OBOC)和一孔 - 两种化合物(OB2C)组合化学反应特别适合于发现ECM模拟物或其他功能性配体针对干细胞的独特细胞表面受体。遗传标记的Olig2-GFP敲入HESC/IPSC报告基因将用作拟议组合库筛选中的读数,以将二分化为寡头胚胎祖细胞进行定位分化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KIT S LAM其他文献

KIT S LAM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KIT S LAM', 18)}}的其他基金

A Mannose 6-Phosphate Decorated Transformable Nanoplatform for Targeted Uptake in HER2+ Tumors
用于 HER2 肿瘤靶向摄取的甘露糖 6-磷酸盐修饰的可转化纳米平台
  • 批准号:
    10381225
  • 财政年份:
    2021
  • 资助金额:
    $ 19.21万
  • 项目类别:
HER2-targeting transformable nanotherapeutic platform against HER2+ cancers
针对 HER2 癌症的可转化纳米治疗平台
  • 批准号:
    10524157
  • 财政年份:
    2020
  • 资助金额:
    $ 19.21万
  • 项目类别:
HER2-targeting transformable nanotherapeutic platform against HER2+ cancers
针对 HER2 癌症的可转化纳米治疗平台
  • 批准号:
    10737741
  • 财政年份:
    2020
  • 资助金额:
    $ 19.21万
  • 项目类别:
HER2-targeting transformable nanotherapeutic platform against HER2+ cancers
针对 HER2 癌症的可转化纳米治疗平台
  • 批准号:
    10348732
  • 财政年份:
    2020
  • 资助金额:
    $ 19.21万
  • 项目类别:
HER2-targeting transformable nanotherapeutic platform against HER2+ cancers
针对 HER2 癌症的可转化纳米治疗平台
  • 批准号:
    10553132
  • 财政年份:
    2020
  • 资助金额:
    $ 19.21万
  • 项目类别:
Therapeutic Targeting Agents for Ovarian Cancer
卵巢癌的治疗靶向药物
  • 批准号:
    9477423
  • 财政年份:
    2015
  • 资助金额:
    $ 19.21万
  • 项目类别:
Therapeutic Targeting Agents for Ovarian Cancer
卵巢癌的治疗靶向药物
  • 批准号:
    9259922
  • 财政年份:
    2015
  • 资助金额:
    $ 19.21万
  • 项目类别:
The rodent eye as a non-invasive window for understanding cancer nanotherapeutics
啮齿动物的眼睛是了解癌症纳米疗法的非侵入性窗口
  • 批准号:
    9751792
  • 财政年份:
    2015
  • 资助金额:
    $ 19.21万
  • 项目类别:
Genetically encoded reporters of integrated neural activity for functional mapping of neural circuitry
综合神经活动的基因编码报告器,用于神经回路的功能映射
  • 批准号:
    9130272
  • 财政年份:
    2014
  • 资助金额:
    $ 19.21万
  • 项目类别:
Genetically encoded reporters of integrated neural activity for functional mapping of neural circuitry
综合神经活动的基因编码报告器,用于神经回路的功能映射
  • 批准号:
    8934232
  • 财政年份:
    2014
  • 资助金额:
    $ 19.21万
  • 项目类别:

相似国自然基金

LAMC2结合MYH9和MYH10抵抗肺癌细胞内质网应激与凋亡
  • 批准号:
    82302973
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于lncNEAT1竞争性结合miR-130a-3p调控BMP6通路探讨二至天癸方抑制颗粒细胞凋亡的表观遗传学机制
  • 批准号:
    82274573
  • 批准年份:
    2022
  • 资助金额:
    52.00 万元
  • 项目类别:
    面上项目
子宫内膜异位症中CRMP4与E3泛素连接酶RNF138竞争性结合Cav1.3抑制细胞凋亡的机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
子宫内膜异位症中CRMP4与E3泛素连接酶RNF138竞争性结合Cav1.3抑制细胞凋亡的机制研究
  • 批准号:
    82260305
  • 批准年份:
    2022
  • 资助金额:
    32.00 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Thymic selection abnormalities in Type 1 Diabetes
1 型糖尿病的胸腺选择异常
  • 批准号:
    10717714
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
RLIP, Mitochondrial Dysfunction in Alzheimer’s Disease
RLIP,阿尔茨海默病中的线粒体功能障碍
  • 批准号:
    10901025
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
A novel genetic mutation reveals the molecular and cellular mechanisms of severe recurrent skin inflammation
一种新的基因突变揭示了严重复发性皮肤炎症的分子和细胞机制
  • 批准号:
    10679177
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
Unmet needs for specific subsets of EGFR mutated lung cancer
EGFR 突变肺癌特定亚型的需求未得到满足
  • 批准号:
    10441928
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
Targeted drug delivery system to overcome blood-brain barrier and therapeutic resistance to current standard of care in Glioblastoma
靶向药物输送系统可克服血脑屏障和对胶质母细胞瘤现行护理标准的治疗耐药性
  • 批准号:
    10659749
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了